mivenion is committed to bridge diagnosis and treatment for patients who are in strong need for personalized medical solutions. Xiralite, a fluorescence optical system to perform the Rheumascan examination, is the first product of mivenion on the market. Rheumascan is an imaging diagnostic procedure for patients with inflammatory diseases in the hands. The most unique feature of Xiralite is its capability to quantitatively monitor treatment efficacy. Due to the capability of Xiralite to exactly measure inflammation, doctors can reduce the number of treatment failures by early adjustment of the individual treatment.
Research and pharmaceutical development at mivenion is performed in the area of targeted therapeutics. Development candidates exert novel modes of action and high specificity for molecular pathways of inflammation and autoimmune disease. mivenion has also generated proprietary technologies for diagnostic imaging of biological drugs used for treatment of inflammation and autoimmune disease. The company is interested to establish partnerships with renowned pharmaceutical or Biotech companies.